There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
NCT05655507
Recruiting
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
Gender:
Female
Ages:
Between 12 years and 17 years
Trial Updated:
12/01/2023
Locations: Sage Investigational Site, Cincinnati, Ohio
Conditions: Major Depressive Disorder
Register for Updates
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
NCT03763643
Recruiting
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Gender:
All
Ages:
Between 1 year and 65 years
Trial Updated:
12/01/2023
Locations: University of Cincinnati, Cincinnati, Ohio +1 locations
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Platinum - Sterling Research Group - Springdale, Cincinnati, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
NCT06160310
Recruiting
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
Gender:
Female
Ages:
All
Trial Updated:
11/28/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Register for Updates
Developing an EEG Probe for Studying and Modulating Cognitive Control
NCT05612659
Recruiting
This study aims to investigate effects of transcranial current stimulation (tES) and transcutaneous direct current stimulation (tsDCS) associated changes on fronto-parietal EEG and cognitive performance in patients with post stroke depression (PSD)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Post-stroke Depression
Register for Updates
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
NCT05911568
Recruiting
TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Register for Updates
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Recruiting
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzyme... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio +3 locations
Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Register for Updates
Continuous Passive Motion Following Fixation of Pelvic and Knee Fractures
NCT04389749
Recruiting
The investigators will directly compare the visual analog scale scores and narcotic pain medication requirements in the patients who have continuous passive motion (CPM) versus those who do not during the course of the hospital admission following an open reduction internal fixation surgery for acetabular fracture, supracondylar femur fracture, or a tibial plateau fracture.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Univrsity of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Fractures, Bone
Register for Updates
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
11/27/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Oximeters and Skin Pigment: Impact of Skin Pigmentation on Accuracy of Pulse Oximetry
NCT05690269
Recruiting
Finger pulse oximetry SpO2 is widely used to estimate arterial oxygen saturation SaO2. Current Spo2 targets do not take into consideration the many variables that affect that correlation in particular skin pigmentation. This study aims to evaluate different FDA approved pulse oximeters (Nonin co-pilot, massimo Radical 7, Philips-standard of care monitor, innovo premium iP900BP, nellcor PM1000N, Nano100) with SaO2 reference values obtained by an arterial blood gas in subjects with different skin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Hypoxemia, Hyperoxia, Pigment Skin
Register for Updates
HRV as a Marker of Treatment Response in PAH Arterial Hypertension
NCT04451850
Recruiting
This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/27/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Pulmonary Arterial Hypertension
Register for Updates
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Recruiting
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Gender:
All
Ages:
4 months and above
Trial Updated:
11/21/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Register for Updates